Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD

BACKGROUND: The oral selective phosphodiesterase-4 inhibitor roflumilast (ROF) reduces exacerbations in patients with severe COPD. Adverse events (AEs) can cause early ROF discontinuation. Alternative dosing strategies may help patients continue their therapy. METHODS: In this multicenter, double-bl...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Int J Chron Obstruct Pulmon Dis
Glavni autori: Watz, Henrik, Bagul, Nitin, Rabe, Klaus F, Rennard, Stephen, Alagappan, Vijay KT, Román, Jonas, Facius, Axel, Calverley, Peter MA
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2018
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5846760/
https://ncbi.nlm.nih.gov/pubmed/29563781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S154012
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items